Roche's Perjeta wins priority review for earlier use; FDA rebuffs new Xarelto use in stent patients;

 @FiercePharma: Will the new weight loss drugs ever prosper? The NYT ticks off the odds stacked against them: Article | Follow @FiercePharma

> Roche's ($RHHBY) breast-cancer treatment Perjeta stepped on the FDA's priority-review track for a new use in patients who haven't yet had surgery. Release

> The FDA pulled back from approving a new use for Johnson & Johnson ($JNJ) and Bayer's clot-fighter Xarelto, to reduce the rate of stent thrombosis in patients with acute coronary syndrome. Report

> The private equity firm Blackstone Group aims to cash in on India's Emcure Pharma, which has filed for a potentially $120 million initial public offering; the firm has a significant minority stake. Report

> Abbott Laboratories ($ABT) is among the baby formula makers under investigation in China for potential violations of anti-monopoly laws. Report

> The effects of new-generation anticoagulant Xarelto can be partially reversed by prothrombin complex concentrates in the event of severe bleeding, a new study found. Release

> Several Indian drugmakers won FDA approval to sell their versions of Merck & Co.'s ($MRK) migraine drug Maxalt-MLT, including Aurobindo Pharma and Glenmark. Report

Medical Device News

 @FierceMedDev: Zoll grabs Minnesota startup with FDA challenges. News | Follow @FierceMedDev

 @MarkHFierce: Today's Dx Extra: a look at a colon cancer test that could detect tumor cells before they take root. DxExtra | Follow @MarkHFierce

 @DamianFierce: Our latest industry voices piece: A Dx insider weighs in on the implications of SCOTUS' MYGN ruling. More | Follow @DamianFierce

 @MichaelGFierce: 'Bioadhesive' coating helps oral drugs deliver payload. Item | Follow @MichaelGFierce

> Roche buys blood diagnostics outfit for $220M. Story

> Sequenta raises $20M for cancer diagnostics. Report

> ArthroCare forks over $45M for sinus surgical tool company. News

Biotech News

 @FierceBiotech: UPDATED: A long lineup of potential buyers crowds Onyx picture. Article | Follow @FierceBiotech

 @JohnCFierce: MannKind shoulders $160M in debt for PhIII inhaled-insulin gamble. Story | Follow @JohnCFierce

 @RyanMFierce: Celgene, others regenerate biotech Tengion's finances with $33.6M. Report | Follow @RyanMFierce

> Achillion shares skid lower after FDA puts a hold on hep C drug. More

> What's the most valuable drug in the global pipeline? Report

Pharma Manufacturing News

 @CarlyHFierce: 160 of India's manufacturing facilities prepared for new EU regulations going into effect today. Item | Follow @CarlyHFierce

>  With Aspen deal, Merck finally able to shrink legacy Organon sites. Story

> Med Prep slapped with consent decree as FDA eyes compounders. More

> Glass particles once again trigger Fresenius Kabi recall. Article

> King Pharma settles for $2.2M after violating pharma emissions standards. Story

Biotech Research News

 @EmilyMFierce: Mouse models predict chemo treatment response in humans. Report | Follow @EmilyMFierce

> Texas A&M launches multimillion-dollar genomics research project. More

> Report: U.K. health body stifling stem cell research. News

> Nonprofit licenses MS mouse model to Biogen Idec to develop new therapies. Story

And Finally... Lottery tickets as rewards for staying HIV-free cut infections by 25% in an African study. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.